ITRM (Iterum Therapeutics PLC) Market Value to Book Value Ratio

Iterum Therapeutics plc (ITRM) relies on the expertise of a tight-knit circle of top researchers attracted by generous grants and focuses on developing antibiotics for the outpatient treatment of urinary tract infections. The price action with a metric at the level of -0.20 demonstrates the asset's dynamics. The business is currently transitioning to active sales of its oral drug in the US following FDA approval through specialized distribution channels.

The indicator is calculated as the quotient of the business's market value divided by its net equity. This metric determines the premium or discount of the market valuation relative to tangible assets. For the biotech company Iterum Therapeutics plc (ITRM), this is critical due to the high cash burn rate and FDA regulatory risks. By analyzing the market-to-book value chart, an investor can identify abnormal deviations from historical trading ranges.